ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
도파민 작용제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 7.5%를 나타내 36억 9,000만 달러로 성장할 것으로 예상됩니다. 예측기간 동안의 성장은 신경질환 유병률 증가, 세계 인구 고령화, 연구 및 임상시험 증가, 병용요법 확대, 인지도 및 진단률 상승으로 인한 것으로 예측됩니다. 이 기간에 예상되는 주요 동향으로는 맞춤형 의료 및 유전자 프로파일링의 이용, 웨어러블 약물전달 시스템의 개발, 의약품 개발에 있어서의 AI와 머신러닝의 통합, 서방형 제제의 진보, 약물전달에의 나노기술의 응용 등이 있습니다.
신경 질환의 이환율 증가는 도파민 작용제 시장 성장을 현저하게 촉진할 것으로 예측됩니다. 뇌, 척추, 신경에 영향을 미치는 신경 질환은 운동, 인지, 행동과 관련된 문제를 일으킵니다. 이러한 유병률 증가는 알츠하이머병이나 파킨슨병 등의 질환이 노화와 함께 일반적으로 되기 때문에 평균 수명이 길어진 것이 주된 원인입니다. 도파민 작용제는 뇌에서 도파민 수용체를 자극하여 파킨슨병과 같은 질병을 치료하는 데 사용되며 운동 조절을 강화하고 증상을 완화하는 데 도움이 됩니다. 예를 들어 알츠하이머병의 케어, 지원, 연구에 초점을 맞춘 미국의 비영리 단체인 알츠하이머병 협회(Alzheimer's Association)가 발표한 'Alzheimer's Disease Facts and Figures' 보고서에 따르면 2022년에는 65세 이상의 미국인 중 650만명이 알츠하이머형 치매로 진단되었으며, 그 수는 2024년까지 690만명으로 증가했습니다. 그 결과, 신경질환의 유병률 증가는 도파민 작용제 시장 확대를 견인하고 있는 것으로 보입니다.
도파민 작용제 시장의 주요 기업은 환자 복용 어드히어런스를 높이고 부작용을 최소화하며 신경 질환에 대한 맞춤형 치료 솔루션을 제공하기 위해 유연한 복용량 단일 요법과 같은 혁신에 유의하십시오. 유연한 도즈 단일 요법은 복용량을 조정할 수 있는 단일 요법입니다. 2024년 11월, 미국의 바이오 의약품 회사인 아비사는 제3상 TEMPO-2 시험에서 양호한 결과가 얻어졌습니다고 보고했습니다. 주요 목표를 달성하고 일상 운동 동작의 유의한 개선이라는 중요한 부차적 목표를 달성했습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 도파민 작용제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 도파민 작용제 시장 : 성장률 분석
세계의 도파민 작용제 시장 실적 : 규모와 성장(2019-2024년)
세계의 도파민 작용제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 도파민 작용제 전체 시장(TAM)
제6장 시장 세분화
세계의 도파민 작용제 시장 : 제품 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
에르고트 기반 도파민 작용제
비에르고트 기반 도파민 작용제
세계의 도파민 작용제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
비경구
경피 패치
세계의 도파민 작용제 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
기타 약국
세계의 도파민 작용제 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
파킨슨병
하지 불안 증후군(RLS)
고프로락틴혈증
세계의 도파민 작용제 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
재택 케어 설정
세계의 도파민 작용제 시장 : 에르고트 기반 도파민 작용제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
브로모크립틴
카베르골린
퍼골라이드
세계의 도파민 작용제 시장 : 비에르고트 기반 도파민 작용제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
프라미펙솔
로피니롤
로티고틴
아포모르핀
제7장 지역별/국가별 분석
세계의 도파민 작용제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 도파민 작용제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
도파민 작용제 시장 : 경쟁 구도
도파민 작용제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
GlaxoSmithKline plc : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH
Otsuka Pharmaceutical Co. Ltd.
Intas Pharmaceuticals Ltd.
UCB Pharma SA
Dr. Reddy's Laboratories Ltd.
H. Lundbeck A/S
Lupin Limited
Luye Pharma Group Ltd.
ACADIA Pharmaceuticals Inc.
Kissei Pharmaceutical Co. Ltd.
Shodhana Laboratories Pvt. Ltd.
Oceanic Pharmachem Pvt. Ltd.
AffaMed Therapeutics Holdings Limited
Schwarz Pharma AG
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
도파민 작용제 시장(2029년) : 새로운 기회를 제공하는 국가
도파민 작용제 시장(2029년) : 새로운 기회를 제공하는 부문
도파민 작용제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Dopamine agonists are medications that activate dopamine receptors in the brain, mimicking the effects of natural dopamine. These medications are commonly used to manage disorders caused by low dopamine activity or impaired dopamine signaling.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main types of dopamine agonists are ergot-based dopamine agonists and non-ergot-based dopamine agonists. Ergot-based dopamine agonists are derived from ergot alkaloids and work by activating dopamine receptors in the brain to help manage neurological and hormonal conditions. These medications are available in various forms, including oral, parenteral (injectable), and transdermal patches. They are distributed through various channels, such as hospital pharmacies, retail pharmacies, and other pharmacy outlets. Ergot-based dopamine agonists are commonly used in the treatment of conditions such as Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia. Key end users include hospitals, clinics, and home care settings.
The dopamine agonist market research report is one of a series of new reports from The Business Research Company that provides dopamine agonist market statistics, including the dopamine agonist industry global market size, regional shares, competitors with the dopamine agonist market share, detailed dopamine agonist market segments, market trends, and opportunities, and any further data you may need to thrive in the dopamine agonist industry. This dopamine agonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The dopamine agonists market size has grown strongly in recent years. It will grow from$2.57 billion in 2024 to $2.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historic period can be attributed to the increasing incidence of Parkinson's disease, a rise in the diagnosis of restless legs syndrome (RLS), expansion of reimbursement coverage, growing research funding for central nervous system (CNS) disorders, and increasing healthcare awareness.
The dopamine agonists market size is expected to see strong growth in the next few years. It will grow to$3.69 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth during the forecast period can be attributed to the rising prevalence of neurological disorders, the aging global population, an increase in research and clinical trials, the expansion of combination therapies, and rising awareness and diagnosis rates. Key trends expected during this period include the use of personalized medicine and genetic profiling, the development of wearable drug delivery systems, the integration of AI and machine learning in drug development, advancements in extended-release formulations, and the application of nanotechnology for drug delivery.
The rising incidence of neurological disorders is expected to significantly drive the growth of the dopamine agonist market. Neurological disorders, which impact the brain, spine, or nerves, cause issues related to movement, cognition, and behavior. This increase in prevalence is largely due to longer life expectancies, as conditions such as Alzheimer's and Parkinson's become more common with age. Dopamine agonists are used to treat disorders such as Parkinson's disease by stimulating dopamine receptors in the brain, helping to enhance motor control and alleviate symptoms. For example, the Alzheimer's Disease Facts and Figures report from the Alzheimer's Association, a US-based nonprofit focused on Alzheimer's care, support, and research, indicates that in 2022, 6.5 million Americans aged 65 and older were diagnosed with Alzheimer's dementia, a number projected to rise to 6.9 million by 2024. As a result, the growing prevalence of neurological disorders will continue to drive the expansion of the dopamine agonist market.
Leading companies in the dopamine agonist market are focusing on innovations such as flexible-dose monotherapy to enhance patient adherence, minimize side effects, and offer more tailored treatment solutions for neurological disorders. Flexible-dose monotherapy involves a single drug with an adjustable dosage, allowing healthcare providers to customize the treatment based on the patient's unique needs and responses. For instance, in November 2024, AbbVie Inc., a US-based biopharmaceutical company, reported positive results from its Phase 3 TEMPO-2 trial, where investigational tavapadon, a flexible-dose monotherapy (5-15 mg once daily), showed significant improvements in motor function among early Parkinson's disease patients. The trial met its primary goal with a substantial reduction in MDS-UPDRS Parts II and III scores and achieved important secondary objectives, indicating meaningful improvements in daily motor activities. Tavapadon is the first D1/D5 partial agonist being investigated for once-daily Parkinson's treatment.
In August 2024, AbbVie, a US-based biopharmaceutical company, acquired Cerevel Therapeutics for $8.7 billion. This strategic acquisition allows AbbVie to enhance its neuroscience portfolio by gaining access to Cerevel's innovative pipeline of treatments targeting psychiatric and neurological disorders. Cerevel Therapeutics Holdings Inc. is a US-based biopharmaceutical company focused on developing therapies for neurological and psychiatric conditions.
Major players in the dopamine agonists market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Intas Pharmaceuticals Ltd., UCB Pharma S.A., Dr. Reddy's Laboratories Ltd., H. Lundbeck A/S, Lupin Limited, Luye Pharma Group Ltd., ACADIA Pharmaceuticals Inc., Kissei Pharmaceutical Co., Ltd., Shodhana Laboratories Pvt. Ltd., Oceanic Pharmachem Pvt. Ltd., AffaMed Therapeutics Holdings Limited, Schwarz Pharma AG
North America was the largest region in the dopamine agonists market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dopamine agonist report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the dopamine agonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dopamine agonist market includes sales of pramipexole, ropinirole, rotigotine, apomorphine, bromocriptine, and cabergoline. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dopamine Agonists Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on dopamine agonists market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for dopamine agonists ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dopamine agonists market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Ergot Based Dopamine Agonists; Non Ergot Based Dopamine Agonists
2) By Route of Administration: Oral; Parenteral; Transdermal Patches
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Pharmacies
4) By Application: Parkinson's Disease; Restless Legs Syndrome (RLS); Hyperprolactinemia
5) By End User: Hospitals; Clinics; Home Care Settings
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Dopamine Agonists Market Characteristics
3. Dopamine Agonists Market Trends And Strategies
4. Dopamine Agonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Dopamine Agonists Growth Analysis And Strategic Analysis Framework
5.1. Global Dopamine Agonists PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Dopamine Agonists Market Growth Rate Analysis
5.4. Global Dopamine Agonists Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Dopamine Agonists Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Dopamine Agonists Total Addressable Market (TAM)
6. Dopamine Agonists Market Segmentation
6.1. Global Dopamine Agonists Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ergot Based Dopamine Agonists
Non Ergot Based Dopamine Agonists
6.2. Global Dopamine Agonists Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Transdermal Patches
6.3. Global Dopamine Agonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Other Pharmacies
6.4. Global Dopamine Agonists Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Parkinson's Disease
Restless Legs Syndrome (RLS)
Hyperprolactinemia
6.5. Global Dopamine Agonists Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Home Care Settings
6.6. Global Dopamine Agonists Market, Sub-Segmentation Of Ergot Based Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bromocriptine
Cabergoline
Pergolide
6.7. Global Dopamine Agonists Market, Sub-Segmentation Of Non Ergot Based Dopamine Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pramipexole
Ropinirole
Rotigotine
Apomorphine
7. Dopamine Agonists Market Regional And Country Analysis
7.1. Global Dopamine Agonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Dopamine Agonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
